Phagocytes and the Leishmania Parasite: A Marriage of Convenience

Mitali Chatterjee

doi:10.1055/s-0040-1712833

Annals of the National Academy of Medical Sciences (India), Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Ann Natl Acad Med Sci 2018; 54(04): 231-244
DOI: 10.1055/s-0040-1712833

Original Article

Phagocytes and the Leishmania Parasite: A Marriage of Convenience

Autor*innen

Mitali Chatterjee

Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata

Abstract

als PDF herunterladen

ABSTRACT

The current drive by the Government of India to eliminate Leishmaniasis has pinpointed post-kala azar dermal leishmaniasis (PKDL) as the strongest contender for the disease reservoir. This emphasizes the necessity to consider the eradication of PKDL as top priority, and hinges on its early diagnosis and management. We undertook this challenge and have provided insights into Leishmania biology, by focusing our efforts in (i) delineating the immunopathogenesis of PKDL, a disease unique to South Asia (ii) developing diagnostic/prognostic tools for monitoring antileishmanial treatment in patients with visceral leishmaniasis and PKDL. In order to delineate the immunopathogenesis of PKDL, it was established that the parasite adopts multiple approaches to deviously manipulate host monocytes/macrophages, and thus facilitate parasite survival and disease progression. The parasite adopts a multipronged approach that includes attenuation of the oxidative burst within phagocytes, polarization of monocytes/ macrophages towards alternate activation, enhancement of CD8 T-cell exhaustion and a decreased presence of Langerhans cells. Identification of these immunological changes have allowed for development of biomarkers that have been exploited to develop diagnostic and prognostic markers for monitoring the disease progression, either in terms of antibody based markers, or quantification of the parasite load, the latter being the most definitive approach. Measurement of parasite load has proved to be an effective tool for monitoring the effectiveness of chemotherapy. Taken together, the identification of biomarkers and new chemotherapeutic modalities has helped in improved management and potential elimination of leishmaniasis.

Keywords

Leishmania biology - post-kala azar dermal leishmaniasis (PKDL) - visceral leishmaniasis - Th-associated cytokines - Toll-like receptors - antimonials - miltefosine

PDF (895 kb)

Referenzen

References
1 Burza S, Croft SL, Boelaert M (2018). Leishmaniasis. Lancet 392: 951-970.
2 World Health Organization (2005). Regional Technical Advisory Group on Kala-azar Elimination. Report of the first meeting, Manesar, Haryana, 20-23 December 2004. New Delhi: WHO Regional Office for South-East Asia.
3 Zijlstra EE, Alves F, Rijal S, Arana B, Alvar J (2017). Post-kala-azar dermal leishmaniasis in the Indian subcontinent: a threat to the South-East Asia Region Kala-azar Elimination Programme. PLoS Negl Trop Dis 11: e0005877.
4 Mukhopadhyay D, Dalton JE, Kaye PM, Chatterjee M (2014). Post kala-azar dermal leishmaniasis: an unresolved mystery. Trends Parasitol 30: 65-74.
5 Kaye P, Scott P (2011). Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol 9:604-615.
6 C r oft SL, C oo mbs GH ( 20 03). Leishmaniasis current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19: 502-508.
7 Martinez FO, Helming L, Gordon S (2009). Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 27: 451-483.
8 MukhopadhyayD, Mukherjee S, Roy S, et al (2015). M2 polarization of monocytes-macrophages is a hallmark of Indian post kala-azar dermal leishmaniasis. PLoS Negl Trop Dis 9:e0004145.
9 Gordon S (2003). Alternative activation of macrophages. Nat Rev Immunol 3: 23-35.
10 Sica A, Mantovani A (2012). Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122: 787-795.
11 Raes G, Van den Bergh R, De Baetselier P, et al (2005). Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells. J Immunol 174:6561.
12 Martinez FO, Helming L, Milde R, et al (2013). Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. Blood 121: e57-e69.
13 Chatterjee M, Moulik S, Dey D, Mukhopadhyay D, Mukherjee S, Roy S (2018). Molecular regulation of macrophage class switching in Indian Post Kala-azar dermal Leishmaniasis (PKDL). In: Molecular Biology of Kinetoplastid Parasites. HK Majumder (ed). Caister Academic Press
14 Ziegler-Heitbrock L, Ancuta P, Crowe S, et al (2010). Nomenclature of monocytes and dendritic cells in blood. Blood 116: e74-e80.
15 Griffin MD, Xing N, Kumar R (2003). Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu Rev Nutr 23: 117-145.
16 Ganguly S, Das NK, Panja M, et al (2008). Increased levels of IL-10 and IgG3 are hallmarks of Indian Post kala-azar dermal leishmaniasis. J Infect Dis 197: 1762-1771.
17 Ganguly S, Mukhopadhyay D, Das NK, et al (2010). Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian Post kala-azar dermal Leishmaniasis. J Invest Dermatol 130:1013-1022.
18 von Stebut E, Belkaid Y, Jakob T, et al (1998). Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin derived dendritic cells: implications for the initiation of anti-Leishmania immunity. J Exp Med 188: 1547-1552.
19 Mukherjee S, Mukhopadhyay D, Braun C, et al (2015). Decreased presence of Langerhans cells is a critical determinant for Indian Post kala-azar dermal leishmaniasis. Exp Dermatol 24: 232-234.
20 Sundar S (2001). Drug resistance in Indian visceral Leishmaniasis. Trop Med Int Health 6: 849-854.
21 Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M (2002). Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739-1746.
22 Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW (2010) Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362: 504- 512.
23 World Health Organization (2004). Regional Strategic Framework for Elimination of Kala-azar from the SouthEast Asia Region (2005–2015). New Delhi: WHO Regional Office for SouthEast Asia.
24 WHO (2007). Regional Technical Advisory Group on kala-azar elimination. Report of the Second Meeting, Kathmandu, Nepal, 20 October–2 November 2006. New Delhi: World Health Organization, Regional Office for SouthEast Asia. WHO Project: CCP CPC 050.
25 Banjara MR, Gurung CK, Uranw S, Pandey K (2015). Internal Assessment of Visceral leishmaniasis Elimination Programme of Nepal. Public Health and Infectious Disease Research Center, Kathmandu, Nepal, 2015.
26 World Health Organization. Health Statistics (2015). http://apps.who.int/iris/bitstream/10665/170250/1/978924069 4439_eng.pdf?ua=1&ua=1
27 Pandey BD, Pun SB, Kaneko O, Pandey K, Hirayama K (2011). Expansion of visceral leishmaniasis to the western hilly part of Nepal (Case report). Am J Trop Med Hyg 84: 107-108.
28 Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM (2003). Post-kala-azar dermal leishmaniasis (Review). Lancet Infect Dis 3:87-98.
29 Ganguly S, Das NK, Barbhuiya JN, Chatterjee M (2010). Post-kala-azar dermal leishmaniasis-an overview. Int J Dermatol 49: 921-931.
30 Chappuis F, Sundar S, Hailu A, et al (2007). Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5: 873-882.
31 Thakur CP (2016). Is elimination of kala-azar feasible by 2017? Indian J Med Res 144: 799-802.
32 Moulik S, Chaudhuri SJ, Sardar B, et al (2018). Monitoring of parasite kinetics in Indian post kala azar dermal leishmaniasis. Clin Inf Dis 66: 404-410.
33 Das NK, Singh SK, Ghosh S, et al (2011). Case series of misdiagnosis with rK39 strip test in Indian leishmaniasis. Am J Trop Med Hyg 84: 688-691.
34 Ghosh S, Das NK, Mukherjee S, et al (2015). Inadequacy of 12-Week miltefosine treatment for Indian post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg 93: 767-769.